News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
688,428 Results
Type
Article (39430)
Company Profile (306)
Press Release (648692)
Section
Business (204784)
Career Advice (2003)
Deals (35475)
Drug Delivery (87)
Drug Development (80993)
Employer Resources (168)
FDA (16116)
Job Trends (14859)
News (345808)
Policy (32547)
Tag
Academia (2548)
Alliances (49430)
Alzheimer's disease (1234)
Approvals (16047)
Artificial intelligence (130)
Bankruptcy (354)
Best Places to Work (11556)
Biotechnology (217)
Breast cancer (121)
Cancer (1083)
Cardiovascular disease (97)
Career advice (1672)
Cell therapy (234)
Clinical research (64362)
Collaboration (389)
Compensation (197)
COVID-19 (2546)
C-suite (95)
Data (1120)
Diabetes (153)
Diagnostics (6159)
Earnings (84945)
Employer resources (146)
Events (109975)
Executive appointments (310)
FDA (16653)
Funding (352)
Gene therapy (177)
GLP-1 (579)
Government (4338)
Healthcare (18688)
Infectious disease (2631)
Inflammatory bowel disease (110)
Interviews (308)
IPO (16330)
Job creations (3658)
Job search strategy (1429)
Layoffs (417)
Legal (7888)
Lung cancer (170)
Manufacturing (177)
Medical device (13185)
Medtech (13190)
Mergers & acquisitions (19218)
Metabolic disorders (403)
Neuroscience (1511)
NextGen Class of 2024 (6534)
Non-profit (4476)
Northern California (1479)
Obesity (231)
Opinion (183)
Patents (102)
People (56592)
Phase I (20009)
Phase II (28360)
Phase III (21126)
Pipeline (455)
Postmarket research (2554)
Preclinical (8523)
Radiopharmaceuticals (236)
Rare diseases (218)
Real estate (5936)
Regulatory (21583)
Research institute (2315)
Resumes & cover letters (350)
Southern California (1304)
Startups (3614)
United States (13494)
Vaccines (550)
Weight loss (168)
Date
Today (129)
Last 7 days (805)
Last 30 days (3825)
Last 365 days (35750)
2024 (32785)
2023 (40177)
2022 (51287)
2021 (55836)
2020 (54157)
2019 (46644)
2018 (35124)
2017 (32222)
2016 (31629)
2015 (37706)
2014 (31454)
2013 (26499)
2012 (28770)
2011 (29426)
2010 (27525)
Location
Africa (716)
Arizona (192)
Asia (37327)
Australia (6105)
California (3337)
Canada (1287)
China (248)
Colorado (145)
Connecticut (152)
Europe (80001)
Florida (458)
Georgia (116)
Illinois (344)
Indiana (197)
Kansas (97)
Maryland (576)
Massachusetts (2611)
Michigan (157)
Minnesota (272)
New Jersey (952)
New York (958)
North Carolina (702)
Northern California (1479)
Ohio (141)
Pennsylvania (845)
South America (1094)
Southern California (1304)
Texas (464)
Utah (90)
Washington State (361)
688,428 Results for "neurocrine biosciences inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Biotech Beach
Neurocrine Biosciences to Participate at Investor Conferences in June 2024
Neurocrine Biosciences, Inc. will participate at two upcoming investor conferences in June.
May 29, 2024
·
2 min read
Business
Neurocrine Biosciences Announces CEO Succession Plan - May 28, 2024
Neurocrine Biosciences, Inc., announced that Kevin Gorman, Ph.D., will retire as Chief Executive Officer of Neurocrine on October 11, 2024.
May 28, 2024
·
14 min read
Press Releases
Neurocrine Biosciences to Participate at Investor Conferences in November
November 5, 2024
·
2 min read
Neuropsychiatric disorders
Neurocrine Scraps Schizophrenia Candidate After Phase II Failure
BMO Capital Markets analyst Evan Seigerman said luvadaxistat’s inconsistencies between mid-stage trials raise questions about Neurocrine Biosciences’ developmental efforts moving forward.
September 13, 2024
·
2 min read
·
Tristan Manalac
Business
Neurocrine Biosciences Reports First Quarter 2024 Financial Results
Neurocrine Biosciences, Inc. announced its financial results for the first quarter ended March 31, 2024 and provided an update on its 2024 financial guidance.
May 1, 2024
·
16 min read
Biotech Beach
Neurocrine Biosciences to Participate at Virtual Investor Conferences in March
Neurocrine Biosciences, Inc. will participate at two upcoming virtual investor conferences in March.
March 11, 2024
·
2 min read
Biotech Beach
Neurocrine Biosciences to Participate at Investor Conferences in March 2024
Neurocrine Biosciences, Inc. will participate at three upcoming investor conferences in March.
February 27, 2024
·
2 min read
Biotech Beach
Neurocrine Biosciences to Present at the BofA Securities 2024 Health Care Conference
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the BofA Securities 2024 Health Care Conference at 11:20 a.m. Pacific Time (2:20 p.m. Eastern Time) on Tuesday May 14, 2024 in Las Vegas.
May 7, 2024
·
1 min read
Drug Development
Neurocrine Biosciences Presented CAHtalyst™ Phase 3 Pediatric and Adult Studies, CAHtalog™ Registry and Disease- and Glucocorticoid-Related Comorbidities Data in CAH at ENDO 2024
Neurocrine Biosciences, Inc. presented information from its neuroendocrinology pipeline at the Endocrine Society Annual Meeting.
June 3, 2024
·
15 min read
Biotech Beach
Neurocrine Biosciences Supports Tardive Dyskinesia Awareness Week by Advocating for Routine Screening and Monitoring
Neurocrine Biosciences, Inc. today renewed its commitment to increasing awareness and advancing care for people living with TD during Tardive Dyskinesia Awareness Week, May 5-11.
May 6, 2024
·
8 min read
1 of 68,843
Next
